HUMAN STUDIES // RESULTS // CAUTIONS
PT-141 Results: What Helped and What Failed
Researchers shaped the drug from earlier tanning work. Later studies didn't erase common nausea or the limits you need to see.
The plain answer on the results
The main PT-141 results came from women covered by the approval. Against placebo, a comparison injection with no medicine, desire edged up and distress fell [3].
The gain lasted in a longer follow-up, which found no new safety issue. Nausea kept showing up, though [4].
Some PT-141 findings were disappointing. A hamster study found no increase in how rewarding sex seemed [6].
Later reviewers called the benefit in women modest [3]. A journal attached a formal warning, an Expression of Concern, to an older men's study because it may not be reliable [7].
I wouldn't hide those misses while checking the results with you. No dose here was chosen for you, your health, or your body.
What changed in the main trials
Final Phase 3 tests followed 1267 women for 24 weeks. They got 1.75 mg of bremelanotide or placebo, an empty shot [3].
Question 13 showed less worry about low desire. The paper lists .001 for desire and .001 for worry; chance was unlikely, but average changes stayed small.
All women were still having periods [3]. You can't apply the result to your body.
What gains and harms lasted
During a 52-week follow-up of 684 women, desire gains lasted and no new safety risk appeared [4]. Nausea affected 40.4%, flushing affected 20.6%, and headache affected 12.0%.
In 2022, researchers gave the drug to 31 women and used scans during sexual pictures. Desire stayed higher for 24 hours, while brain regions responded in a new pattern [5].
A 2026 review joined several trials and found gains in desire and physical readiness for sex [15]. An overall score covering several parts of sex life rose too.
A longer view doesn't erase those side effects. You might face both benefit and harm in your own day.
What published PT-141 reviews agree and doubt
Published reviews say bremelanotide acts in the brain and can help some women upset because desire had faded [8][13]. Only a few choices have approval.
The reviews warn that large final Phase 3 studies may miss parts of women's real sex lives [9]. A score change may not feel useful to you.
They place the drug among choices used before menopause [10]. Doctors still debate how to name and treat low desire [12].
Reviews also find weak spots in studies of the other drugs [11]. These papers sum up studies, not comments from users.
That's the limit I'd keep in view. The reviews can't show what your own body will feel.
What failed to show up or hold up
Female Syrian hamsters received two different amounts of bremelanotide. Brain cells in the reward area didn't change their activity, and sex didn't become more rewarding [6].
Later checks say the gains in women's desire and distress were small and may not matter much in daily life [3]. You deserve that limit beside the good result.
In 2023, a journal warned readers that a 2008 study of men with erection trouble may not be reliable [7]. The warning means the study is disputed and can't carry much weight.